Sarepta Therapeutics, Inc. SRPT
NASDAQ · United States · Health Technology
$17.57-0.65 (-3.57%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
CAMBRIDGE, Mass., September 30, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rul
CAMBRIDGE, Mass., September 30, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.